Brad Walsh has resigned from the Australian Proteomics Analysis Facility in Sydney, where he served as facilities manager, Walsh told ProteoMonitor. He did not comment on his future plans, except to say that “in a short time I will have a nice end to the story.”
Henry Nowak has joined Caprion Pharmaceuticals as chief financial officer and executive vice president for legal affairs, Montreal-based Caprion said last week.
Nowak most recently served as general counsel and vice president for intellectual property at Paradigm Genetics. He has also held the position of legal and patent counsel at Novartis, Amgen, and Schering-Plough.
AxCell Biosciences, a subsidiary of Cytogen, is searching for a chief executive officer, and will form a scientific advisory board, the Newtown, Penn.-based company said last week.
Until a CEO is found, Michael Becker, formerly vice president and investor relations officer at the company, will serve as interim CEO, a previously unfilled position. John Rodwell will continue to serve as AxCell’s president and chief technology officer, and will head the company’s scientific advisory board.
GeneFormatics has appointed Vincent Gotz as its chief business officer, the San Diego-based company said last week.
Prior to joining GeneFormatics, Gotz served as vice president for business development at Epicyte Pharmaceuticals. He has also held management positions at Dura Pharmaceuticals.